Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.
about
Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effectEpstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection.Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome.Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area.Hypoxia inducible factor-1 alpha activation of the JCV promoter: role in the pathogenesis of progressive multifocal leukoencephalopathyHypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1)Toxoplasma gondii activates hypoxia-inducible factor (HIF) by stabilizing the HIF-1alpha subunit via type I activin-like receptor kinase receptor signaling.Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.Beclin-1-independent autophagy positively regulates internal ribosomal entry site-dependent translation of hypoxia-inducible factor 1α under nutrient deprivation.Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma.The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo.Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma.Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response.Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines.MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling.Oncogenic viruses and tumor glucose metabolism: like kids in a candy store.Changes in expression induced by Epstein-Barr Virus LMP1-CTAR1: potential role of bcl3.EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma.Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration.Upregulation of special AT-rich-binding protein 1 by Epstein-Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer.A mechanism for induction of a hypoxic response by vaccinia virus.EBV reactivation as a target of luteolin to repress NPC tumorigenesis.Downregulation of ATOH8 induced by EBV-encoded LMP1 contributes to the malignant phenotype of nasopharyngeal carcinomaBC-box protein domain-related mechanism for VHL protein degradation.IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells.Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma.Interdependence of hypoxic and innate immune responsesInterferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic propertiesViruses as key regulators of angiogenesis.Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity.Targeting tumor hypoxia in nasopharyngeal carcinoma.Hypoxia-inducible factor-1 as a therapeutic target in cancer.Role of epigenetics in EBV regulation and pathogenesis.The role of Epstein-Barr virus in epithelial malignancies.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment.
P2860
Q24294513-4D1EE20A-1684-4CFE-8DC5-154EAA6A337AQ24317074-CE7CD6C6-9493-4A18-94FF-60BBF7200BC7Q33374284-F00E9BB0-83F6-4EAD-AB79-CBAE1773BB50Q33562717-A006BABE-35C0-4D7C-8EF9-90D867FA30BAQ33650637-4AEA437A-169C-4A57-8893-4DD0A60FC896Q33796549-F5EA1CC4-7FA2-47D0-BFEF-1E405067D8B4Q33842381-AF024931-D888-4820-B73C-4A200922CD2EQ33987481-BA7D43F1-6106-4D58-A94F-A8460C7BB05CQ34009713-D8E66CF5-2A5E-4E46-9208-21031A7F3239Q34094330-1E1724D3-0E7A-4188-8288-AACABDA6DC09Q34171808-BDE48A27-D779-48C3-B037-E4E8E358F815Q34171822-6C215E03-367A-4B77-9AA8-B6610362DC1EQ34365765-C7FFF526-D12A-44D9-B651-A690F210D1E8Q34745799-A83E0194-FC4F-4257-86A3-AF928CE7EF34Q34973323-B5ACA23C-415F-449D-8C95-8C2D2B323B58Q35067738-53E4ADD8-98B6-4C9C-8F33-F40F5014927DQ35139337-AFDB4CAD-C9F5-434A-91A4-E880C347C066Q35363169-679FC0A9-830E-42EF-9A92-0956EDA90E6BQ35635449-564F256D-89C5-40FB-BEF4-B9B9555D2092Q35671327-2EA2316C-6977-4DA0-99E5-CB8BB5F3B10BQ35677629-4CB36E28-5C22-4C9F-9A44-CB5A52691E29Q35742407-7376620D-09C3-42D6-BF99-52A19D95AA2CQ36174662-3250A972-24A3-44E2-A135-2CF4C1E02D71Q37006707-8E281722-7598-4E88-9ED3-C8FC2A84C28BQ37049417-744F10E1-697F-4066-9F33-E10A2C3CB52EQ37109915-B1039520-2B49-44EB-9D78-36D666DBAD5CQ37295787-7E256988-DEC9-4CCA-97B9-45F9ABFC3EB6Q37318235-8291D042-A91F-4FDB-B735-C39014214308Q37331575-86C55956-BD82-4712-8DC6-461F990EF95DQ37575613-5CA02C3C-3D2D-4DB2-B98A-DBD932DD5C2CQ37586121-1833CBA9-D2A8-4DF4-AD75-3AE0F52C9099Q37596432-936F4EE0-13E6-432F-86D9-961FB20D3C7DQ37871527-A84B62DB-8896-45EA-926C-6C92DEE7B6E5Q37938966-4BE23A71-7F77-42FC-A1A9-57EB9DD261C7Q37959387-CDE72DAE-D5D1-45CB-930F-788058B2A85BQ38061671-2255B477-71BF-4FC4-9455-BB8C58283EC0Q38232195-82DAB00D-0E67-4104-8487-6CD8BF073E9DQ38253914-4B4AA416-3DE5-49AE-B6DF-3E3843414444Q38607549-E7A1CC31-7E88-416D-AD2E-0E7CBCF00780Q38800732-2234B175-65FD-45A4-9591-75BB29A23A8B
P2860
Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@ast
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@en
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@nl
type
label
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@ast
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@en
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@nl
altLabel
ஆராய்ச்சிக்கட்டுரை
@ta
prefLabel
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@ast
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@en
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@nl
P2093
P2860
P1476
Epstein-Barr virus latent memb ...... oxia-inducible factor 1 alpha.
@en
P2093
Joseph S Pagano
Mitsuru Furukawa
Naohiro Wakisaka
Satoru Kondo
Shigeyuki Murono
Tomokazu Yoshizaki
P2860
P304
P356
10.1128/MCB.24.12.5223-5234.2004
P407
P577
2004-06-01T00:00:00Z